Cost-effectiveness of Osimertinib in First-Line Treatment of EGFR -Mutated Advanced NSCLC

This cost-effectiveness analysis of data from the FLAURA randomized clinical trial evaluates the incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year of osimertinib as a first-line treatment for patients with EGFR-mutated advanced non–small cell lung cancer in the United States and Brazil.

https://ift.tt/2JfHF0H